GlobeNewswire

Rally Report 2026: The momentum is growing. But too many girls are still being left behind
12/11/2026
Canadian Women & Sport's flagship research, with Canadian Tire Jumpstart Charities, finds girls' sport participation has held its gains and points to what it will take to help more girls start and keep playing [...]
Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
12/11/2026
U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection through 2044 Form B [...]
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
12/11/2026
BOSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
R1 Takes Aim at Healthcare’s Fragmented Revenue Cycle with Six Connected AI Solutions
12/11/2026
New Phare Denials module joins Phare OS, giving health systems a pathway from point solutions to a connected revenue operating system spanning pre- and post-bill operations Phare OS adoption now spans more than $275 [...]
Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
12/11/2026
Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers Presented new AP01 data at ERS Congress and published detailed results from AP02 Phase 1 trials in [...]
Vivani Medical Announces Positive Top-Line Results from SLIM-1™, a First in Human Phase 1 Trial of NPM-139 (semaglutide implant) and Wegovy (weekly semaglutide injections) in Obese and Overweight Subjects
12/11/2026
Strong NPM-139 safety and tolerability profile: -0 of 10 NPM-139 subjects experienced adverse events reported as treatment related -5 of 10 Wegovy subjects (control group) experienced adverse events reported as [...]
Artelo Biosciences Provides Business Update and Reports 2026 Third Quarter Financial Results
12/11/2026
Continued Progress Across Pipeline Supports Expanded Therapeutic Opportunities SOLANA BEACH, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical [...]
Hyro Achieves Oracle Validated: Oracle Health Endpoint Validation Expertise for Delivering Proven Agentic AI EHR Integration
12/11/2026
Validation confirms Hyro’s Care OnCue™ appointment workflows run on Oracle Health’s existing interfaces, reducing custom integration effort and cost of ownership for health systems NEW YORK, Nov. 12, 2026 (GLOBE [...]
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
12/11/2026
Initiated the Company’s third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors Started first backfill cohorts in the ongoing Phase 1b NECTINIUM [...]
Kyverna Therapeutics Announces Completion of BLA Submission for Miv-cel in Stiff Person Syndrome and Reports Third Quarter 2026 Financial Results
12/11/2026
BLA submission for miv-cel in SPS completed with request for priority review Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first approved therapy for SPS and first approved [...]
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
12/11/2026
WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with [...]
CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol “OPHI”
12/11/2026
OPHI marks another important step in CollPlant’s strategy to expand and focus its operations built around LightSolver’s all-optical Laser Processing Unit (LPU)™ Rehovot, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) -- [...]
IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update
12/11/2026
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 [...]
Randomized Study of Non-Invasive Autonomic Neuromodulation for Long COVID Published Online in Neuromodulation
12/11/2026
Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore’s cervical vagus nerve [...]
Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
12/11/2026
– VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 – – Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in [...]
Baird Medical Enters South Korea Market through Strategic Distribution Partnership with ALLIS MED
12/11/2026
ALLIS MED to lead regulatory certification process and serve as exclusive distributor for Baird Medical Microwave Ablation (MWA) products in key market NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Baird Medical [...]
Evaxion announce 2027 financial calendar
12/11/2026
COPENHAGEN, Denmark, November 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces its financial [...]
Axiom Biosciences Announces Regulation Crowdfunding Offering With Wefunder Community Round
12/11/2026
Regulation Crowdfunding offering provides retail investor access to Axiom’s clinical-stage biotechnology platform SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences , a clinical-stage biotechnology company [...]
CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors
12/11/2026
VANCOUVER, Washington, Nov. 12, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum